STOCK TITAN
  1. Home
  2. Sec-filings
  3. PAHC
  4. [Form 4] PHIBRO ANIMAL HEALTH CORP Insider Trading Activity

BFI Co. trims 328 Phibro Animal Health (PAHC) shares under Rule 10b5-1

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Phibro Animal Health Corporation insider activity centered on an entity linked to its President and CEO, Jack Bendheim. On January 7, 2026, BFI Co., LLC, a 10% owner, sold 328 shares of Phibro’s Class A Common Stock at a weighted average price of $40.0877 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. Following this sale, BFI held 38,872 shares indirectly reported, over which Bendheim exercises voting and dispositive power and may be deemed to share voting and investment power through BFI.

Separately, Jack Bendheim directly held 16,840 shares of Class A Common Stock after the reported transactions. The price range for the sold shares was from $40.035 to $40.26, with the reported price reflecting the weighted average across multiple trades.

Positive

  • None.

Negative

  • None.
Insider BENDHEIM JACK, BFI Co., LLC
Role President and CEO | 10% Owner
Sold 328 shs ($13K)
Type Security Shares Price Value
Sale Class A Common Stock 328 $40.0877 $13K
holding Class A Common Stock -- -- --
Holdings After Transaction: Class A Common Stock — 38,872 shares (Indirect, See); Class A Common Stock — 16,840 shares (Direct)
Footnotes (4)
  1. F1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
  2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $40.26. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. F4. The reported securities are directly held by Jack Bendheim.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

Who are the reporting persons in this Phibro Animal Health (PAHC) Form 4?

The Form 4 lists Jack Bendheim, Phibro Animal Health’s President, CEO, director, and 10% owner, and BFI Co., LLC, which is also a 10% owner. Bendheim exercises voting and dispositive power over BFI and may be deemed to share voting and investment power over securities held by BFI.

How many Phibro Animal Health (PAHC) shares did BFI Co., LLC sell and at what price?

On January 7, 2026, BFI Co., LLC sold 328 shares of Phibro Animal Health Class A Common Stock. The reported weighted average sale price was $40.0877 per share, with individual trade prices ranging from $40.035 to $40.26.

Was the Phibro Animal Health (PAHC) share sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025. Such plans are pre-arranged trading programs for buying or selling shares.

How many Phibro Animal Health (PAHC) shares does BFI Co., LLC hold after the transaction?

After the January 7, 2026 sale, BFI Co., LLC is reported as holding 38,872 shares of Phibro Animal Health Class A Common Stock indirectly reported through the Form 4.

How many Phibro Animal Health (PAHC) shares does Jack Bendheim directly own after this Form 4?

The Form 4 states that 16,840 shares of Phibro Animal Health Class A Common Stock are directly held by Jack Bendheim following the reported transactions.

What is the relationship between Jack Bendheim and BFI Co., LLC in this Phibro Animal Health (PAHC) filing?

The filing explains that the reported securities sold and held in one line are directly held by BFI Co., LLC. Jack Bendheim exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over those securities, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BENDHEIM JACK
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 01/07/2026 S(1) 328 D $40.0877(2) 38,872 I See(3)
Class A Common Stock 16,840 D(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
BENDHEIM JACK
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
BFI Co., LLC
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $40.26. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
4. The reported securities are directly held by Jack Bendheim.
/s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim 01/08/2026
/s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR